Massachusetts Life Sciences Center Launches Impact Catalyst Program

Today, the Massachusetts Life Sciences Center (MLSC) announced the launch of the Impact Catalyst program, a seed-stage, non-dilutive funding initiative designed to accelerate high-risk translational research for underserved patient populations in historically underinvested disease areas.  

The Impact Catalyst program provides milestone-based grants of up to $250,000 to early-stage life science startups to address persistent funding gaps in hard-to-commercialize fields. By pairing flexible, non-dilutive capital with committed private investors participating in the company’s first institutional financing round (seed round), the program aims to reduce early-stage risk, catalyze additional investment, and position promising startups for future commercialization while strengthening Massachusetts’ life sciences ecosystem. Impact Catalyst is structured to help activate and close the financing round by directly mobilizing investor participation and strategic capital within defined life sciences sector focus areas. 



“The life sciences industry is a cornerstone of the Commonwealth’s economy and a key driver of long-term growth,” said Economic Development Secretary and MLSC Board Co-Chair Eric Paley. “Through initiatives like the Impact Catalyst program, we are helping early-stage companies gain the traction they need at crucial moments, strengthening our innovation pipeline and ensuring Massachusetts remains competitive in a rapidly evolving global market.” 

“Massachusetts has built its reputation by combining world-class innovation with strong networks of support,” said MLSC President and CEO Kirk Taylor, MD. “By standing behind entrepreneurs at their earliest stages, we can help translate groundbreaking research into meaningful advancements in health care for patients with limited treatment options.” 

Focus areas for the program include medical devices and diagnostics, health equity solutions, women’s health, psychiatric diseases and pain management, and microbiome and antibiotic innovation. By directing resources to fields with significant medical and social burden, the program supports transformative solutions for underserved patient groups while building a strong pipeline of early-stage life sciences companies across the Commonwealth. 

Additionally, today the MLSC launched the latest round of the Massachusetts Next Generation (MassNextGen) Initiative, continuing the Center’s commitment to supporting diverse entrepreneurs while expanding opportunity across the Massachusetts life sciences ecosystem. 

The application period for the Impact Catalyst program and the MassNextGen Initiative will run from March 16 through June 12, 2026 at 1 p.m. EST. 

For interested companies, the MLSC offers info sessions on its initiatives that support diverse entrepreneurs and early-stage life science companies. Register today for an upcoming info session:  

• March 24, 2026, at 11 a.m. EST, virtual – register  

• April 30, 2026, at 2 p.m. EST, virtual – register  

• May 18, 2026, at 1 p.m. EST, virtual – register 

Visit the MLSC’s Impact Catalyst program page to learn more. For questions, please reach out to: impactcatalyst@masslifesciences.com. 



About the Massachusetts Life Sciences Center     
The Massachusetts Life Sciences Center (MLSC) is a quasi-public economic development and investment agency dedicated to supporting the growth and development of the life sciences in Massachusetts, home to the most verdant and productive life sciences ecosystem in the world. Through public-private funding initiatives, the MLSC supports innovation, research and development, commercialization, and manufacturing activities in the fields of biopharma, medical device, diagnostics and digital health. Since 2008, the MLSC has strategically deployed more than $1.1 billion in Massachusetts, through a combination of grants, loans, capital infrastructure investments, tax incentives and workforce development programs. These investments have created thousands of jobs and propelled the development of new therapies, devices and scientific advancements that are improving patient health and well-being in Massachusetts and beyond.